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Epileptic encephalopathy can be induced by inborn metabolic defects that may be rare individually but in aggregate represent a
substantial clinical portion of child neurology. These may present with various epilepsy phenotypes including refractory neonatal
seizures, early myoclonic encephalopathy, early infantile epileptic encephalopathy, infantile spasms, and generalized epilepsies
which in particular include myoclonic seizures. There are varying degrees of treatability, but the outcome if untreated can often be
catastrophic. The importance of early recognition cannot be overemphasized. This paper provides an overview of inborn metabolic
errors associated with persistent brain disturbances due to highly active clinical or electrographic ictal activity. Selected diseases
are organized by the defective molecule or mechanism and categorized as small molecule disorders (involving amino and organic
acids, fatty acids, neurotransmitters, urea cycle, vitamers and cofactors, and mitochondria) and large molecule disorders (including
lysosomal storage disorders, peroxisomal disorders, glycosylation disorders, and leukodystrophies). Details including key clinical
features, salient electrophysiological and neuroradiological findings, biochemical findings, and treatment options are summarized
for prominent disorders in each category.

1. Introduction
Inherited metabolic epilepsies are disorders that, while individually rare, are in aggregate a substantial clinical portion
of child neurology, as well as a complex field of knowledge
for physicians, investigators, and students to tackle. A subset
of these disorders can lead to the development of epileptic
encephalopathy, that is, a brain disturbance due to highly
active clinical or electrographic ictal activity. The epileptologist may view these from the viewpoint of syndromic phenotypes such as early myoclonic encephalopathy, early infantile
epileptic encephalopathy, infantile spasms, and myoclonic
epilepsies. They have various degrees of treatability at present,
with some requiring prompt diagnosis and intervention to
avoid otherwise catastrophic outcomes. Careful consideration of metabolic disorders in patients presenting with
epileptic encephalopathy is therefore warranted, and to this
end, we hope a review may be helpful.
This paper provides an overview of inborn metabolic
errors associated with epileptic encephalopathy, summarizing key clinical features and underlying biochemistry,
salient electrophysiological and neuroradiological findings,

and primary treatment options where appropriate. Examples
of specific disorders are discussed, with full listings of the
multiple enzyme defects and diseases in particular categories
presented in tables. The range of inherited metabolic disorders has been organized by the category of molecules or the
biochemical process involved: for example, small molecule
disorders include dysfunction involving amino, organic, or
fatty acids, neurotransmitters, the urea cycle, vitamers and
cofactors, and disorders of the mitochondria. Large molecule
diseases cover defects in glycosylation, lysosomal and peroxisomal function, and leukodystrophies.

2. Small Molecule Disorders
2.1. Amino and Organic Acid Disorders. Amino acidopathies
and organic acidemias, resulting from disorders in amino
or fatty acid catabolism, present with seizures and cognitive, behavioral, or motor disturbances resulting from the
accumulation of toxic intermediaries, or possible structural
damage [1]. Some may induce an epileptic encephalopathy.
Seizure types and EEG findings vary, though myoclonic
epilepsies predominate, and diffuse background slowing is
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a common EEG finding. More typical EEG findings in metabolic encephalopathies are burst suppression, hypsarrhythmia, and generalized spike-wave discharges. Table 1 lists
the protean disorders along with the enzyme defect and
metabolites detected on diagnostic studies.
2.1.1. Methylmalonic Acidemia and Cobalamin Deficiencies.
The finding of elevated methylmalonic acid can be caused
by a number of distinct disorders including defects in
the vitamin B12-related enzymes cobalamin A, B, C, or D
and methylmalonyl CoA mutase (MUT). Early myoclonic
encephalopathy, as well as other epilepsies and epileptic
encephalopathies, has been associated with this finding. The
most common methylmalonic acidemia involving cobalamin
is cobalamin C deficiency (Figure 1); individuals may present
in infancy or early childhood with seizures and progressive
encephalopathy. Patients presenting with status epilepticus
have also been reported. Treatment with hydroxycobalamin
is effective, including prenatal supplementation in affected
families but may not reverse existing neurological injury in
delayed diagnoses [3].
2.1.2. Propionic Acidemia. Propionic acidemia (PA) is caused
by defects in the enzyme propionyl CoA carboxylase
and commonly presents with lethargy, vomiting, metabolic
acidemia, and sometimes hyperammonemia [4]. A severe
presentation of this disease in infancy with infantile spasms
and hypsarrhythmia is reported [5]; myoclonic and generalized seizures are common in early childhood and infancy and
typically evolve into mild generalized and absence seizures
later in life [6].
2.1.3. Ethylmalonic Acidemia. Ethylmalonic encephalopathy
is usually lethal in infancy or early childhood and has
a severe presentation including seizures, brain structural
malformations, neurodevelopmental regression, pyramidal
and extrapyramidal symptoms, chronic diarrhea, and dermatological findings including petechiae and acrocyanosis.
MRI has shown frontotemporal atrophy, enlargement of the
subarachnoid spaces, and basal ganglia T2-weighted hyperintensities [7]. EEGs may worsen over time, with multifocal
spike and slow waves and background disorganization [8].
2.1.4. 3-Hydroxy-3-Methylglutaric Acidemia. When untreated, dysfunction of the enzyme 3-hydroxy-3-methylglutaryl
CoA lyase (which cleaves 3-hydroxy-3-methylglutaryl CoA
into acetyl CoA and acetoacetate) leads to metabolic acidosis with absent ketone production, lactic acidemia, hypoglycemia hepatomegaly, and lethargy, possibly progressing to
coma and death. Seizures are linked in most cases to lactic
acidemia or hypoglycemia and are associated with multifocal
spike-wave discharges on EEG [8]. Some presentations show
particular association with white matter lesions, dysmyelination, and cerebral atrophy on neuroimaging [9, 10].
2.1.5. Glutaric Acidemia. Dysfunction of the enzyme glutaryl CoA dehydrogenase prevents the metabolism of tryptophan, hydroxylysine, and lysine, resulting in increased
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urine glutaric acid metabolites. This is a cerebral organic
acidopathy, with predominantly neurological symptoms featuring macrocephaly, increased subarachnoid spaces, and
progressive dystonia and athetosis with striatal injury [11].
Seizures can be a presenting sign and are seen during acute
encephalopathic events [12, 13]. EEGs show background slowing with generalized spike-and-wave and mixed multifocal
discharges [8, 14]. Therapy using a low-protein diet (especially
low lysine and tryptophan), carnitine supplementation, and
aggressive emergency management can significantly improve
the outcomes. The antiepileptic valproate should be avoided,
however, because it is believed to affect acetyl CoA/CoA
ratios and may exacerbate metabolic imbalance [13].
2.1.6. 3-Methylglutaconic Acidurias. Five subtypes of 3-methylglutaconic aciduria (MGA) have been categorized (Table 1);
all are cerebral organic acidopathies resulting from defects
in the leucine catabolic pathway. Neurological and developmental symptoms are central in all five types although
seizures are prominent mainly in Type I. Patients with
Type I MGA present with leukoencephalopathy and epileptic
encephalopathy with psychosis and depression, in addition
to ataxia, optic atrophy, and sensorineural hearing loss.
These are often accompanied by systemic issues including
cardiomyopathy, liver and exocrine pancreatic dysfunction,
and bone marrow failure [15]. EEGs show diffuse slowing
and white matter lesions can be seen on MRI, usually in a
supratentorial location [8, 15, 16].
2.1.7. Canavan Disease. Canavan disease is primarily a disease of demyelination. It is thought to be caused by brain
acetate deficiency resulting from a defect of N-acetylaspartic
acid (NAA) catabolism [17]. Accumulation of NAA, a compound thought to be responsible for maintaining cerebral
fluid balance, can lead to cerebral edema and neurological
injury. Presentation of Canavan disease includes progressive
epileptic encephalopathy with developmental delay, macrocephaly, leukodystrophy, and optic atrophy [18, 19]. Seizures
often begin in the second year of life, and treatment is
primarily supportive, including antiepileptic medications.
2.1.8. D- and L-2-Hydroxyglutaric Aciduria. D-2-Hydroxyglutaric aciduria results from the loss of enzyme function
in either D-2-hydroglutaric dehydrogenase or hydroxyacidoxoacid transhydrogenase, which metabolizes GHB (gammahydroxybutyrate). Though presentations vary, severe cases
manifest in the neonatorum with encephalopathy, intractable
epilepsy, and cardiomyopathy. Seizures are present in almost
all cases, and MRI findings have included signal alterations in
the basal ganglia and diencephalon, as well as agenesis of the
corpus callosum.
The enantiomer, L-2-Hydroxyglutaric aciduria, is a disorder of alpha ketoglutarate synthesis. It presents with neurodevelopmental delay, generalized seizures, and progressive
ataxia. Multifocal spike-waves and burst suppression can
be seen on EEGs [20, 21], and characteristic MRI findings
include cerebellar atrophy, subcortical white matter loss, and
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Table 1: Amino acidemias and organic acidopathies.

Disorder
Propionic acidemia (PA)

Defective enzyme
Propionyl CoA carboxylase

Methylmalonic acidemia (MMA)

Methylmalonic mutase
Cobalamin A
Cobalamin B

Methylmalonic acidemia with
homocysteinuria, cobalamin C/D

Cobalamin C
Cobalamin D

Isovaleric acidemia (IVA)

Isovaleryl dehydrogenase

3-Methylcrotonylglycinuria (3MCC)

3-Methylcrontonyl
CoA carboxylase

3-Hydroxy-3-methylglutaryl CoA lyase
deficiency

3-Hydroxy-3-methylglutaryl CoA Lyase

Malonic aciduria
2-Methyl-3-hydroxybutyrl CoA
dehydrogenase deficiency

Malonyl CoA decarboxylase
2-Methyl-3-hydroxybutyryl
CoA dehydrogenase

Ethylmalonic encephalopathy

Branched chain Keto-dehydrogenase

Beta-ketothiolase deficiency

3-Methyl acetoacetate
thiolase

Biotinidase deficiency and
Holocarboxylase synthetase deficiency

Biotinidase
Holocarboxylase synthetase

2-Methyl butyryl CoA dehydrogenase

2-Methyl butyryl CoA dehydrogenase

Glutaric acidemia I

Glutaryl CoA dehydrogenase

Canavan disease

3-Methylglutaconyl CoA
hydratase (Type I)
Barth (Type II)
Costeff (Type III)
Type IV
Type V
Aspartoacylase

L-2-Hydroxyglutaric aciduria

L-2-Hydroxyglutarate dehydrogenase

3-Methylglutaconic acidurias

D-2-Hydroxyglutaric aciduria
4-Hydroxybutyric Aciduria
Fumaric aciduria

D-2-Hydroxyglutarate dehydrogenase
Hydroxy-oxoacid
transhydrogenase
Succinate semialdehyde dehydrogenase
Fumarate hydratase

Diagnostic metabolites
Propionylcarnitine (C3; P)∗
Methylcitrate (U)∗
3-Hydroxypropionic acid (U)
Methylmalonic acid (P, U)
Propionylcarnitine (C3; P)
Methylcitrate (U)
3-Hydroxypropionic acid
Methylmalonic acid (P, U)
Propionylcarnitine (C3; P)
Methylcitrate (U)
Total homocysteine (P)
3-Hydroxypropionic acid (U)
Isovaleric acid (U)
Isovalerylcarnitine (C5; P)
3-Hydroxyisovaleric acid (U)
3-Methylcrotonylglycine (U)
Hydroxyisovalerylcarnitine (C5OH; P)
Hydroxyisovalerylcarnitine (C5OH; P)
3-Hydroxy-3-methylglutaric acid (U)
3-Methylglutaconic acid (U)
Malonate (U)
2-Methyl-3-hydroxybutyrate (U)
Tiglylglycine (U)
C4
C5
Ethylmalonic acid (U)
Methylsuccinic acid
C4–C6 acylglycines (P)
C5:1 (P)
2-Methyl-3-hydroxybutyrate (U)
Tiglylglycine (U)
2-Methyacetoacetate (U)
Propionylcarnitine (C3; P)
Hydroxyisovalerylcarnitine (C5OH; P)
Biotinidase enzyme deficiency (P)
Lactate (P, U)
3-Methylcrotonylglycine (U)
Methylcitrate (U)
3-Hydroxypropionic acid (U)
2-Methylglycience (U)
Isovalerylcarnitine (C5; P)
Glutaric acid (U)
3-Hydroxyglutaric acid (U)
Glutaryl carnitine (C5-DC; P)

3-Methylglutaconic acid (U)
Hydroxy-isovalerylcarnitine (P)

N-Acetylaspartic Acid (U)
L-2-Hydroxyglutaric Acid (U)
Lysine (CSF)
D-2-Hydroxyglutaric acid (U)
Gamma-hydroxybutric acid (U)
Fumarate (U)
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Table 1: Continued.

Disorder

Defective enzyme

Maple syrup urine disease (MSUD)

Branched chain Keto-dehydrogenase

Dihydrolipoamide dehydrogenase

MSUD III

Phenylketonuria (PKU)

Phenylalanine hydratase (PAH)

Diagnostic metabolites
Leucine (P)
Alloisoleucine (P)
Dicarboxylic acids (U)
Leucine (P)
Alloisoleucine (P)
Dicarboxylic acids (U)
Lactic acid (P, U)
Phenylalanine (P)
Low tyrosine (P)

(P): plasma, (U): urine. Adapted from Pearl [2].

Cobalamin transport and metabolism
TC

∗

OH-Cbl

TC

OH-Cbl

Lysosome
OH-Cbl

L-methylmalonyl-CoA

cblC
Cbl

Adenosyl-Cbl

Homocysteine
Succinyl-CoA
Methyl-Cbl
Methionine

∗

Mitochondrion

Cytoplasm

TC: Transcobalamin

(Cbl-binding protein)

Cbl: Cobalamin

OH-Cbl: Hydroxycobalamin

Figure 1: Cobalamin transport and metabolism. Hydroxycobalamin (OH-Cbl) enters the cell bound to transcobalamin (TC), a binding
protein. The hydroxycobalamin-transcobalamin complex is broken down inside the lysosome, and the enzyme cobalamin C (CblC) removes
the hydroxyl group to generate free cobalamin (Cbl), which is synthesized via additional steps into methyl- and adenosyl-cobalamin.

symmetric T2-weighted hyperintensities in the cerebellar
dentate nuclei, globus pallidi, and thalami.
2.1.9. Fumaric Aciduria. Seizures are a prominent feature
in fumaric aciduria, due to a defect in the conversion of
fumarate to malate. The disorder can present prenatally
with polyhydramnios and cerebral ventriculomegaly and
manifests in infancy and early childhood with epilepsy, serious neurodevelopmental delay, macrocephaly, opisthotonus,
and vision loss. Status epilepticus is well reported. Diffuse
polymicrogyria, decreased white matter, large ventricles, and
open opercula are seen on neuroimaging [22].
2.1.10. Maple Syrup Urine Disease and Dihydrolipoamide
Dehydrogenase Deficiency. Dysfunction of the enzyme
branched-chain 2-keto dehydrogenase (BCKD) in maple
syrup urine disease (MSUD) prevents normal degradation
of the branched-chain amino acids leucine, isoleucine,
and valine, leading to toxic accumulation of metabolites.

Neurological symptoms present in infancy and include
cerebral edema, seizures, lethargy, vomiting, and “bicycling”
movements [23]. Seizures are related to the cerebral edema
and hyperlycinemia, and these symptoms can progress to
coma and death. The EEG may show a characteristic comblike rhythm (Figure 2). Treatment focuses on removing
leucine from blood with dialysis or by reversing catabolism
through feeding.
Dihydrolipoamide dehydrogenase deficiency, sometimes
referred to as MSUD Type III, is due to a defect in a
subunit of BCKD, as well as 3 other essential enzymes. The
disorder leads to metabolic acidosis and neurological injury,
and patients can present with hypoglycemia, absent ketones,
elevated liver transaminases, and seizures [24]. The disorder
is often fatal at an early age, representing multienzyme failure.
2.2. Disorders of GABA Metabolism. Seizures are an important problem in disorders of the synthesis or degradation of gamma-aminobutyric acid (GABA), the brain’s primary inhibitory neurotransmitter. The most common of

Epilepsy Research and Treatment

5

Figure 2: EEG of 4-day-old infant with MSUD shows comb-like rhythm over the right central (C4) area. (sensitivity 7 mcv/mm, HFF 70 Hz,
time constant 0.5 sec, 8 sec epoch). Pearl [2].

these is succinic semialdehyde dehydrogenase (SSADH)
deficiency, though GABA-transaminase deficiency—while
extremely rare—features a more severe, progressive epileptic encephalopathy. Both are inherited metabolic disorders
affecting GABA degradation.
2.2.1. Succinic Semialdehyde Dehydrogenase Deficiency (4Hydroxybutyric Aciduria). Deficiency of the enzyme succinic
semialdehyde dehydrogenase (SSADH) results in increased
systemic and CSF levels of GABA and its catabolite, 4hydroxybutyric acid (GHB). Patients present with neurodevelopmental delay, expressive language impairment,
hypotonia, hyporeflexia, ataxia, and behavioral disorders
that commonly include obsessive compulsive and attention
deficit hyperactivity disorders. Over 50% of individuals with
SSADH deficiency will develop seizures, most commonly
tonic-clonic and atypical absence seizures [25]. Recurring
status epilepticus and sudden unexpected death in epilepsy
patients (SUDEP) have been reported, the latter associated
with escalating seizure frequency and severity [26]. MRIs
show increased T2-weighted signals in the globus pallidus,
cerebellar dentate nucleus and subthalamic nucleus, and
variably cerebral and cerebellar atrophy [27]. EEGs typically
show generalized spike-wave activity although some may
have partial features and variable hemispheric lateralization
(Figure 3). Treatment is currently limited to antiepileptic and
behavioral medications. While valproate is generally avoided
due to its ability to inhibit any residual enzymatic activity, its
use has been associated with improvement in some patients
with challenging epilepsy including epileptic encephalopathy.
2.3. Fatty Acid Oxidation Disorders. Severe seizures can be
a presenting sign of defects in fatty acid beta-oxidation,
a biochemical process that produces alternatives source of
acetyl-CoA and ketone bodies for energy. Fatty acid oxidation

(FAO) disorders (Table 2) are a large category of diseases that
particularly endanger the CNS and other organ systems that
have high energy demands. Metabolic decompensation can
be triggered by physiological stressors such as fasting, fever,
or physical exertion, and symptoms can appear at any age.
Acute crises resemble Reye syndrome, with cardiomyopathy
and arrhythmia, as well as rhabdomyolysis and hypoketotic
hypoglycemia [28, 29].
Blood and urine laboratory tests are informative towards
a diagnosis, particularly if done while the patient is symptomatic. Treatment is dependent on clinical presentation
and include avoidance of fasting with frequent low-fat and
carbohydrate-rich intake for nonsymptomatic patients and
moderation of physical stress in combination with mediumchain triglyceride (MCT) supplementation for patients symptomatic with myopathy. Patients in metabolic crisis require
close management in an inpatient setting, with immediate
reversal of the catabolism [30, 31].
2.4. Mitochondrial Diseases. Epilepsy is a common secondary
feature of mitochondrial disease, and disorders in this category (Table 3) have been associated with severe epileptic encephalopathy. Seizures can be a logical consequence
of mitochondrial dysfunction: deficient energy generation
disrupts the active maintenance of neuronal membrane
potential, and seizure-induced cellular hyperactivity adds
further oxidative stress to already deficient ATP generation.
Up to 60% of patients with mitochondrial disease develop
seizures, and many of these can be refractory to treatment
[32]. Myoclonic epilepsies are the most commonly reported,
but almost all seizure types have been seen, and individual
patients can often show multiple types.
2.4.1. POLG1 Disease. Mutations in the gene POLG1, which
facilitates mitochondrial DNA replication, have been linked
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(a)

(b)

Figure 3: (a) EEG of 3-year-old female with SSADH deficiency. Note diffuse spike-wave paroxysm with lead-in over right hemisphere. (b)
Same recording as top, showing left-sided spike-wave paroxysm. Pearl [2].

to a range of disease phenotypes, the most prominent being
Alpers’ disease [33] (Figure 4). Alpers-Huttenlocher disease
is a rapidly progressive encephalopathy, causing intractable
epilepsy and diffuse neuronal degeneration. Partial complex
and myoclonic seizures are most common, although the
disorder can evolve to include multiple seizure types [34].
The use of valproate is contraindicated; it has been associated
with liver failure in patients with POLG1 mutations, as well as
epilepsia partialis continua.
A syndrome of myoclonic epilepsy myopathy sensory
ataxia (MEMSA) has also been seen in patients with mutations in POLG1. Seizures, usually focal and often refractory,
begin in young adulthood, though other symptoms including
sensory neuropathy and cerebellar ataxia may occur in

adolescence. Over time, individuals develop cognitive decline
and myopathy [35].
2.4.2. Myoclonic Epilepsy with Ragged Red Fibers (MERRF).
Myoclonic epilepsy with ragged red fibers (referring to the
appearance of affected muscle cells) is a progressive epilepsy
syndrome associated with prominent myoclonus, cognitive
decline, optic atrophy, hearing loss, and myopathy [36]. It
is associated with mtDNA mutations, and symptoms usually
become noticeable in adolescence or young adulthood [37].
EEG findings include focal discharges, atypical spike- or
sharp- and slow-wave discharges, and suppression of this
activity during sleep [38].
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Table 2: Fatty acid oxidation disorders and biochemical characteristics.
Disorder
Carnitine uptake defect (CUD)
(Primary/systemic carnitine deficiency, carnitine transporter OCTN2
deficiency)

Biochemical characteristics
↓↓↓ Carnitine (P)

Carnitine palmitoyltransferase I deficiency (CPT 1A)

↑ Ammonia (P)
↑ Liver enzymes (ALT, AST)

Carnitine palmitoyltransferase II deficiency (CPT II)
(i) lethal neonatal
(ii) infantile
(iii) myopathic

↑ C12–C18 acylcarnitines (P)

Carnitine-acylcarnitine translocase deficiency (CACT)

↑ Ammonia (P)
↑ Liver enzymes (ALT, AST)
↑ Creatine kinase (P)
↑ Long chain acylcarnitines (P)
↓ Free carnitine (P)

Mitochondrial trifunction protein deficiency (TFP)
(i) Isolated long chain Acyl-CoA
Dehydrogenase deficiency (LCHAD)
Very long chain acyl-CoA dehydrogenase deficiency (VLCAD)
Medium chain acyl-CoA dehydrogenase deficiency (MCAD)
Medium chain 3-ketoacyl-CoA thiolase deficiency (MCKAT)
Short chain acyl-CoA dehydrogenase deficiency (SCAD)
Medium/short chain acyl-CoA dehydrogenase deficiency (M/SCHAD)

Glutaric acidemia Type II
2,4-Dienoyl-CoA reductase deficiency
Acyl-CoA dehydrogenase 9 deficiency (ACAD9)

Hypoketotic hypoglycemia
Hypoglycemia (ketotic or nonketotic)
Hypoketotic hypoglycemia
Ketotic lactic aciduria
C6–C12 dicarboxylic aciduria
↑ Ethylmalonic acid (U)
Hyperinsulinemic hypoglycemia
↑ 3-Hydroxybutylcarnitine
↑ 3-Hydroxy butyric acid (U)
↑ 3-Hydroxy glutaric acid (U)
Hypoglycemia
Metabolic acidosis
2-Trans,4-Cis-decadienoylcarnitine (P, U)
Persistent lactic acidosis

Figure 4: 7-year-old boy diagnosed with Alpers’ syndrome presented with encephalopathy, tonic-clonic seizures and myoclonic seizures.
EEG shows high amplitude anterior poorly formed 2-3 Hertz sharp and slow activity. Pearl [2].

2.4.3. Leigh Syndrome. Leigh syndrome, also known as subacute necrotizing encephalomyopathy, can be seen in disorders
involving mitochondrial DNA (as well as nonmitochondrial
disorders). Individuals present with neurologic regression
with worsening hypotonia, spasticity, and brainstem failure
as the disease progresses. Neuroimaging may show bilateral,
symmetric lesions in the basal ganglia, thalami, midbrain,
and brainstem as well as cortical and cerebellar atrophy

[39]. Focal and generalized epilepsy are associated with
this phenotype, and epilepsia partialis continua, as well as
infantile spasms and hypsarrhythmia, has been described
[40].
2.5. Cerebral Folate Deficiency. Cerebral folate deficiency can
be a common end result of diverse metabolic and genetic
conditions (Table 4). A suspected pathology in primary CFD
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Table 3: Mitochondrial disorders and epilepsy.

Category of disorder

Mitochondrial complex deficiencies

Mitochondrial DNA disorders

Other associated syndromes

Syndrome
(i) Complex I deficiency
(ii) Complex II deficiency
(iii) Complex III deficiency
(iv) Complex IV deficiency
(v) Complex V deficiency
(i) mtDNA depletion syndromes
(a) POLG1 disease
(1) Alpers-Huttenlocher disease
(2) Childhood onset epilepsia partialis continua (EPC)
(3) Myoclonic epilepsy myopathy sensory ataxia (MEMSA)
(ii) mtDNA deletion syndromes
(a) Kearns-Sayre syndrome (KSS)
(b) Chronic progressive external ophthalmoplegia (CPEO)
(iii) Myoclonic epilepsy with ragged-red fibers (MERRF)
(iv) Myoclonic epilepsy, lactic acidosis, and stroke (MELAS)
Leigh syndrome

involves impaired transport of folate across the choroid
plexus into the central nervous system. This may be due to
one of multiple causes, including loss of function mutations in
the folate FR1 receptor, blocking autoantibodies to the folate
receptor, or disrupted uptake due to valproic acid. Secondary
folate deficiency can also be seen in inborn metabolic diseases, such as Rett syndrome, 3-phosphoglycerate dehydrogenase deficiency (a congenital serine biosynthesis disorder),
and mitochondrial disorders such as Kearns-Sayre or Alpers
disease [41–44].
Primary cerebral folate deficiency (CFD) is characterized
by normal blood but low CSF levels of 5-methylhydrofolate
(5-MTHF), the physiologically active form of folate. The
common phenotype includes epilepsy, along with neurodevelopmental delay (or regression) and dyskinesias. Individuals with blocking autoantibodies to folate receptors present
in early childhood with intractable generalized tonic-clonic
seizures. In some cases, treatment with high doses of folinic
acid (as opposed to folic acid, which has poor blood-brain
barrier entry) has been reported to ameliorate seizures and
improve neurological function [45].

oral serine and glycine has been reported to significantly
improve seizures, spasticity, behavior, and feeding, as well as
white matter volume and myelination [48, 49].

2.6. Serine Synthesis Defects. Lserine, a nonessential amino
acid, is synthesized from 3-phosphoglycerate by the sequential activity of three enzymes, each with associated disorders
(Table 5). The majority of patients with serine deficiencies are affected by an abnormality in the first step, 3phosphoglycerate dehydrogenase. The clinical phenotype,
which includes congenital microcephaly and psychomotor
retardation with refractory seizures and hypsarrhythmia, is
nonspecific, likely leading practitioners to suspect in utero
processes such as TORCH (Toxoplasmosis, Syphilis, Rubella,
Cytomegalovirus, Herpes simplex, HIV) or static perinatal
difficulties. MRI findings in infantile onset patients have
revealed cortical and subcortical atrophy, as well as delayed
myelination [46]. Juvenile onset has also been reported,
with presentation at school age with absence seizures and
moderate developmental delay [47]. Supplementation with

2.8. Hyperinsulinism-Hyperammonemia (HI-HA). HI-HA is
a syndrome of congenital hyperinsulinism and hyperammonemia that has been related to activating mutations
affecting GDH (glutamate dehydrogenase), a participant in
the insulin secretion pathway. These defects cause GDH to
become insensitive to inhibition, resulting in excess ammonia
production and insulin release and neurological sequelae
from hypoglycemic insults and hyperammonemia [56]. The
clinical constellation of generalized epilepsy, learning disorders, and behavior problems, in the context of hypoglycemia
(both postprandial and fasting) and persistent hyperammonemia, is characteristic.
Hypoglycemic seizures may be the first apparent indication. However, some patients have been observed to experience paroxysms, accompanied by generalized electroencephalographic features, without hypoglycemic episodes.

2.7. DEND Syndrome (Developmental Delay, Epilepsy, and
Neonatal Diabetes). A syndrome that combines the problems
of developmental delay, epilepsy, and neonatal diabetes is
an epileptic channelopathy associated with mutations in
potassium channel and sulfonylurea receptor genes [50].
These mutations permanently “lock in” the KATP channel in
an open state, leading to insufficient insulin release and severe
hyperglycemia within the first six months of life [51–53].
Clinical manifestations include neurodevelopmental delay,
dysmorphic features, hypotonia, and seizures starting as early
as the neonatorum. Infantile spasms with hypsarrhythmia,
as well as severe tonic-clonic and myoclonic epilepsies, are
reported. Neonatal hyperglycemia in DEND can be managed
with insulin or sulfonylureas, but the latter is capable of
bypassing the defective regulation of KATP channels and
may have better efficacy for the neurological phenotype
[50, 54, 55].
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Table 4: Cerebral folate deficiencies.
Disorder or mechanism

Primary cerebral folate deficiency

Folate receptor FR1 defect due to autoantibodies
Folate receptor FR1 defect due to (FOLR1 gene) mutation

Disorders with secondary cerebral folate deficiency

Aicardi-Goutieres syndrome
Alpers syndrome
Isolated Rett syndrome
Kearns-Sayre syndrome
Mitochondrial complex I encephalomyopathy
Valproic acid complications
Table 5: Serine synthesis defects.

Disorder

Epilepsy and neuroimaging features
Infantile phenotype:

3-Phosphoglycerate dehydrogenase
deficiency

Infantile phenotype:
(i) Seizure control or significantly
lowered frequency

(i) intractable seizures
(ii) MRI: hypomyelination and delayed
myelination
Juvenile phenotype:
(i) absence seizures
(ii) MRI: no abnormalities

Phosphoserine Aminotransferase
deficiency

Symptomatic patient:
(i) intractable seizures
(ii) MRI: generalized atrophy, including
cerebellar vermis and pons, white matter
abnormalities
Presymptomatic patient:
(i) MRI: no abnormalities

Phosphoserine phosphatase deficiency

Response to treatment with
L-serine and glycine

Single case, details not reported

(ii) Increased white matter volume
Juvenile phenotype:
(i) Seizure control
(ii) Prevention of neurological
abnormalities
Symptomatic patient:
(i) No clinical response to treatment

Presymptomatic patient:
(i) Prevention of all neurological
abnormalities
Not reported

Adapted from Pearl [2].

This suggests that epilepsy in HI-HA may not be due solely to
low CNS glucose availability [57–59]. HI-HA is manageable
with a combination of dietary protein restriction, glucagon,
antiepileptic medications, and diazoxide, a KATP channel
agonist that inhibits insulin release [60].
2.9. Glucose Transporter 1 Deficiency. Glucose transporter
type I (Glut-1) facilitates the passage of glucose across the
blood-brain barrier, and its dysfunction in the developing
brain leads to the development of a metabolic encephalopathy. CSF shows hypoglycorrhachia associated with normal
plasma glucose and low-to-normal CSF lactate, measured
in a fasting state. A wide array of phenotypes has been
associated with this disorder, but 90% of affected children
develop epilepsy (of various types, including absence, focal,
generalized myoclonic, clonic, tonic, and nonconvulsive status epilepticus) [61]. Microcephaly, ataxia, and psychomotor
delay may be present [62], but patients may also suffer
from epilepsy without any accompanying motor or cognitive

deficiencies. Haploinsufficiency (of the SLC2A1 gene) is
correlated with the severity of symptoms [63]. EEG findings
vary and may be normal, but usually include either focal
or generalized slowing or attenuation, or spike-and-wave
discharges (generalized, focal, or multifocal). Neuroimaging
results may demonstrate diffuse atrophy.
Glucose transporter I deficiency has emerged as the
leading metabolic indication for the ketogenic diet, a dietary
therapy that replaces glucose with ketone bodies as the primary biochemical energy source. Response is rapid, even in
the case of formerly refractory seizures, and treatment should
be maintained long term. Additionally, there are certain
compounds known to inhibit Glut-1, including phenobarbital, diazepam, methylxanthines (theophylline, caffeine), and
alcohol, which should be avoided [64].
2.10. Pyridoxine, Folinic Acid, and Pyridoxal-5 -Phosphate
Dependent Epilepsies. There are various epileptic encephalopathies related to vitamin B6 metabolism (Table 6), and
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Table 6: Pyridoxine and pyridoxal-5 -phosphate-dependent Epilepsies.
Pyridoxine- or folinic-acid-dependent
epilepsies (PDE)

Deficient enzyme

Antiquitin (ATQ)

Vanillactic acid (Urine)
Pipecolic acid (blood, CSF)
AASA∗ (blood, urine, CSF)

Normal, but hypoglycemia and lactic
acidosis have been reported
Absent
↑
↑

Neurotransmitter metabolites (CSF)

(Possible) ↑ 3-Methoxytyrosine

Clinical signs

Postnatal refractory seizures,
gastrointestinal symptoms,
encephalopathy with hyperalertness,
sleeplessness

Blood chemistry

∗

Pyridoxal-5 -phosphate (PLP-)
dependent epilepsy
Pyridox(am)ine phosphate oxidase
(PNPO)
Hypoglycemia and lactic acidosis
common
Present
Normal
Normal
↑ L-DOPA, 3-Methoxytyrosine
↓ Homovanillic acid,
5-Hydroxyindoleacetic acid
Fetal distress and in utero fetal seizures,
postnatal refractory seizures and
encephalopathy

AASA: alpha-aminoadipic semialdehyde. Adapted from Pearl [2].

pyridoxine-dependent epilepsy (PDE) is the prototype,
resulting from a loss of the biologically active pyridoxal5 -phosphate (PLP) due to a dysfunction of the protein
antiquitin (ALDH7A1) [65]. PDE normally presents within
the first hours following birth with serial refractory seizures
responsive to pyridoxine administration. Improvement is
significant and usually rapidly appreciable on EEG [66].
Variants of the disorder that respond to folinic acid instead
of, or in addition to, pyridoxine have also been described,
as well as atypical cases with long asymptomatic periods or
presenting later in infancy (i.e., weeks or months following
birth) [67, 68].
PNPO, or pyridox(am)ine phosphate oxidase, deficiency
is a distinct disorder involving refractory seizures responsive not to pyridoxine but to its biologically active form,
pyridoxal-5 -phosphate (PLP) [69, 70]. This disorder is due
to a defect in the enzyme PNPO, which synthesizes PLP from
precursors pyridoxine-P and pyridoxamine-P [71]. Patients
may present prenatally with fetal seizures and premature
birth and if untreated can progress to status epilepticus and
death. Laboratory and genetic testings are available to confirm these diagnoses (Table 6); trials of systemic pyridoxine
administration require close cardiorespiratory monitoring.
2.11. Urea Cycle Disorders. The urea cycle (Figure 6), the
metabolic mechanism for nitrogen detoxification and
removal, is facilitated by six enzymes and a mitochondrial
transporter and carrier, each being susceptible to dysfunction
(Table 7). In the event of an enzyme or transport defect,
the resulting hyperammonemia can lead to overwhelming
encephalopathy, often accompanied by seizures and
hypotonia that may be exacerbated by metabolic stresses
such as fever or infection [72]. EEG monitoring should be
initiated early in the course of acute treatment, as seizure
activity is thought to be related to hyperammonemic
crises or structural damage, and subclinical electrographic

seizures are reported. Males with OTC deficiency typically
present in the neonatorum and with high mortality, whereas
female heterozygotes can vary in the severity and timing of
presentation depending on hepatic lyonization [72].
The goals of therapy during metabolic crisis are removal
of ammonia through hemodialysis, nitrogen scavenging with
agents including sodium benzoate and sodium phenylacetate
[73], and reversal of catabolism. Immediate antiepileptic therapy is indicated for optimizing treatment; valproate, however,
may interfere with the urea cycle and precipitate metabolic
crises [74]. Maintenance therapy of urea cycle defects hinges
on the restriction of protein intake while providing sufficient
essential amino acids. Orthotopic liver transplant may be
curative, but cannot reverse existing neurologic injury.
2.12. Creatine Biosynthesis and Transport Deficiencies. Half of
the body’s daily requirement of creatine is synthesized from
arginine and glycine by the enzymes AGAT (arginine:glycine
amidinotransferase) and GAMT (guanidino acetate methyl
transferase). A specific creatine transporter, CT1, encoded by
an X-linked gene, facilitates the uptake into tissues. Patients
with deficiencies in creatine synthesis or transport present
with early developmental delay, seizures, neurologic regression, intellectual disability, autistic behavior, hypotonia, and
movement disorders. Females with heterozygous mutations
of the creatine transporter gene may be symptomatic with
more moderate intellectual disability, learning and behavior
problems, and epilepsy [75].
Approximately half of individuals with GAMT deficiency,
and most males with creatine transporter deficiency, develop
epilepsy [76]. Patients with GAMT deficiency have abnormal MRI signals of the globus pallidus and background
slowing and generalized spike-and-wave discharges on EEG.
Individuals with creatine transporter deficiency present with
generalized and partial epilepsy, with EEG usually reported
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Table 7: Urea cycle defects and biochemical characteristics.

Defective enzyme
or component

Citrulline

Arginine Ammonia

Ornithine transcarbamylase

↓

↓

↑

Carbamoylphosphate synthetase I (CPS1)

↓

↓

↑

↑++
(10–100x normal)

↓

↑

↑

↓

↑

N-acetyl glutamate synthase (NAGS)
Argininosuccinate synthase (ASS)
Argininosuccinate lyase (ASL)

↑ Argininosuccinic acid (unique to
ASL deficiency)

Normal in absence of
metabolic stress

Arginase (ARG1)
Ornithine transporter mitochondrial I
(ornithine translocase deficiency)
Citrin (solute carrier family 5) deficiency

Additional biochemical
characteristics
↑ Glutamine
Normal orotic acid
↑ Glutamine
↑ Orotic acid
Reduced CPS1 activity
(NAGS is a vital cofactor)

↑

↑ Homocitrulline
↑ Ornithine

↑

Adapted from Pearl [2].

as showing generalized polyspike or multifocal epileptiform
discharges [77, 78].
Laboratory identification using urine creatine metabolites (Table 8) is necessary to distinguish the three disorders
[79]. In the case of creatine synthesis disorders, treatment
with oral creatine supplementation can improve seizures and
neurological function, and arginine restriction and ornithine
supplementation are utilized in GAMT deficiency. Creatine
transport disorders, however, are not significantly amenable
to therapy other than with traditional antiepileptic medications.
2.13. Glycine Encephalopathy. Glycine encephalopathy is an
inherited disorder of glycine degradation resulting from
defects in the mitochondrial glycine cleavage system (GCS).
The excitatory effects of glycine on the cortex and forebrain,
mediated by N-methyl-D-aspartate(NMDA) receptors, lead
to excess intracellular calcium accumulation and subsequent
neuronal injury with intractable seizures [80]. Based on age
at presentation and clinical outcomes, different categories
of glycine encephalopathy (GE) can be distinguished. The
majority of patients present with a severe neonatal-onset
form, with primarily myoclonic and intractable seizures,
hypotonia, apnea, and coma [81]. Outcomes are generally
poor, particularly in the presence of brain malformations
such as corpus callosum hypoplasia. There are attenuated
forms, lacking congenital malformations, with a better outcome.
Laboratory analyses reveal elevated plasma and CSF
glycine, as well as an increased CSF to plasma glycine
ratio. EEG findings include multifocal epileptiform activity,
hypsarrhythmia, and burst-suppression patterns (Figure 5)
[82]. Treatment with benzoate and a low-protein diet may
reduce glycine levels in plasma, and combined antiepileptic
treatment is necessary for most individuals.

2.14. Sulfide Oxidase Deficiency/Molybdenum Cofactor Deficiency. Sulfite oxidase deficiency due to molybdenum cofactor deficiency (MOCOD) and isolated sulfite oxidase deficiency (ISOD) are inherited disorders of the metabolism
of sulfated amino acids [83]. They typically present in the
first days of life with poor feeding following an uneventful
pregnancy and delivery. Seizures, primarily myoclonic or
tonic-clonic, begin in the first few weeks of life; they can be
refractory to therapy and may develop into status epilepticus
[84]. Signs of encephalopathy with opisthotonus, apnea,
prolonged crying, and provoked erratic eye movements or
myoclonias can be seen, and up to 75% of patients will have
slight dysmorphia including widely spaced eyes, small nose,
puffy cheeks, and elongated face [85].
EEG findings include burst suppression patterns and
multifocal spike-wave discharges [86], and neuroimaging
results are usually profoundly abnormal, including diffuse
cerebral edema evolving into cystic lesions and brain atrophy
within weeks [87]. Low total plasma homocysteinemia is
associated with both ISOD and MOCOD, and hypouricemia
due to secondary xanthine dehydrogenase deficiency can
be indicative of MOCOD. Therapy has historically been
symptomatic, with combination or monoantiepileptics.
2.15. Homocysteinemias. Disorders involving homocysteine
metabolism, specifically methionine and cystathionine synthesis, are characterized by elevated urine and serum
homocysteine in the context of neurological symptoms.
The spectrum of neurological dysfunction in homocysteine metabolism disorders is wide, including epilepsy,
encephalopathy, peripheral neuropathy, ataxia, microcephaly,
and psychiatric disorders. Cystathionine beta-synthetase
(CBS) deficiency is the most common of the homocysteinemias, with severe defects involving multiple systems due to
the essentiality of homocysteine and methionine to normal
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Table 8: Creatine synthesis defects.

Defective enzyme
or component
AGAT (arginine : glycine
amidinotransferase)

Urine
Creatine

Urine GAA
(guanidinoacetate)

Creatine/creatinine
ratio

treatment

↓

↓

Normal

(i) Amenable to creatine therapy

GAMT (guanidine acetate methyl
transferase)

↓

↑

Normal

Creatine transporter

↑

Normal (may be
slightly increased in
males)

↑

(i) Amenable to creatine therapy;
(ii) Dietary restriction of arginine,
with ornithine supplementation
(iii) Antiepileptics may be necessary
for seizure control
(i) Antiepileptics for seizure control
(ii) Creatine supplementation is
ineffective

Table 9: Biochemical characteristics and treatment of homocysteine metabolism disorders.
Defective enzyme

Homocysteine (U, Additional biochemical
P)
characteristics

Treatment

Cystathionine beta-synthase (CBS)

↑

↑ Methionine
↓ Cysteine

Pyridoxine, B12, folate
Methionine-restricted diet
Cysteine supplementation betaine

Methionine synthase (MTR)

↑

Normal or ↑ Folate
Normal or ↑ Cobalamin

High-dose hydroxycobalamin

Methylene tetrahydrofolate reductase (MTHFR)

↑

↓ Methionine

High-dose betaine
Methionine supplementation

∗

(U): urine, (P): plasma.

biochemical function. Focal seizures, stroke, neurodevelopmental delay, and cognitive deficiency, as well as psychosis are
common neurological findings. Marfan-like skeletal symptoms, connective tissue abnormalities in the optic lens, and
vasculopathies causing thrombosis and multiorgan infarcts
may also be present. Treatment and biochemical findings in
CBS, as well as other homocysteine disorders are summarized
in Table 9.
Autosomal recessively inherited deficiency of methylene tetrahydrofolate reductase (MTHFR) may present in
early infancy with severe epileptic encephalopathy [88]. The
presentation with hypotonia, lethargy, feeding difficulties,
and recurrent apnea may progress from seizures to coma
and death. Infantile spasms may also be the presenting
feature, with evolution to multiple seizure types including the
Lennox-Gastaut syndrome. Status epilepticus, both clinical
and subclinical, has been reported. Progressive microcephaly
and global encephalopathy may ensue as seizures continue,
but there is evidence for reversibility with treatment comprised principally of the methyl donor betaine [89].
2.16. Purine and Pyrimidine Defects. Disorders of purine and
pyrimidine metabolism may present with epileptic encephalopathies (Table 10), including adenylosuccinase (adenylosuccinate lyase) deficiency which has a broad phenotypic
spectrum including neonatal seizures [90]. Lesch-Nyhan
disease, or X-linked hypoxanthine-guanine phosphoribosyltransferase deficiency, may result in epileptic seizures, but
these can be difficult to distinguish from the extrapyramidal
manifestations, specifically dystonic spasms, tremor, and

myoclonus. Generalized tonic-clonic seizures are the most
commonly reported epilepsy type in the literature [91, 92].
Treatment with allopurinol is essential for hyperuricemia
and may provide some antiepileptic effect. Antiepileptic drug
choices must weigh the possibility of exacerbating underlying behavioral irritability with levetiracetam and others.
Topiramate and zonisamide are avoided due to the risk of
nephrolithiasis.

3. Large Molecule Disorders
3.1. Disorders of Glycosylation. Disorders of protein glycosylation, due to defects in the synthesis of N- and Olinked glycoproteins, are characterized by multiple organ
system dysfunction, developmental delay, hypotonia, and
epilepsy. Certain of these disorders are associated with
severe encephalopathy, particularly those involving alphadystroglycan, a protein component of the extracellular
matrix, essential to muscle integrity. These are known as
dystroglycanopathies.
3.1.1. Walker-Warburg Syndrome. Walker-Warburg syndrome
(WWS) is a severe dystroglycanopathy which can present at
birth or prenatally with hydrocephalus and encephaloceles
on imaging. Seizures and significant structural abnormalities
(e.g. cerebellar atrophy, hypoplasia of the corpus callosum),
migrational defects (type II lissencephaly), hypomyelination,
and ophthalmologic defects are seen. Life expectancy is less
than three years [93, 94].
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Table 10: Purine and pyrimidine metabolism disorders involving epilepsy.
Disorder

Defective enzyme

Biochemical characteristics

Lesch-Nyhan Disease (LSD)

hypoxanthine-guanine
phosphoribosyl transferase

↑ Uric acid

Adenylosuccinase deficiency

Adenylosuccinate lyase

↑ succinylaminoimidazole
carboxamide riboside
↑ succinyladenosine

Seizure characteristics
Predominantly generalized
tonic-clonic, developing in early
childhood
Neonatal seizures
Severe infantile epileptic
encephalopathy

Figure 5: EEG of term infant with glycine encephalopathy shows burst-suppression pattern. Pearl [2].

3.1.2. Fukuyama Congenital Muscular Dystrophy. Fukuyama
congenital muscular dystrophy (FCMD) classically presents
in the neonatorum or even prenatally (poor fetal movement)
with frequent seizures and severe brain abnormalities (migration defects, cobblestone lissencephaly, delayed myelination,
hypoplasia of the pons, cerebellar cysts). By the age of 3, most
patients develop epilepsy. Muscular degeneration and cardiac
involvement are progressive [95, 96].
3.2. Lysosomal Storage Disorders. Lysosomal storage disorders (LSD) are a major category of diseases that involve
defects in lysosomal enzyme function, lysosomal biogenesis,
activation, trafficking, or membrane transporters. Over twothirds of LSDs are neurodegenerative and some are associated
with epileptic encephalopathy. Table 11 lists lysosomal storage
disorders by subgroup, and prominent examples are covered
below.
3.2.1. Neuronal Ceroid Lipofuscinoses (NCLs). Neuronal ceroid lipofuscinoses are genetically heterogeneous neurodegenerative disorders associated with defects in transmembrane proteins and are characterized by the accumulation
of autofluorescent lipopigments in lysosomes. The symptoms
include cognitive decline, seizures, vision loss, and motor
impairment, though age of onset and clinical course vary
[97]. The development of epilepsy can indicate a more
severe clinical course, though myoclonic seizures should
be distinguished from myoclonus, which is also a frequent
and sometimes progressive feature of this disorder [98].
Generalized cerebral and cerebellar atrophy can be seen on
neuroimaging [99].
3.2.2. Sphingolipidosis and Gaucher Disease. Defects in the
degradation of sphingolipids, an essential component of

myelin sheaths and neuronal tissue, lead to progressive neurodegeneration, epilepsy, peripheral neuropathy, extrapyramidal symptoms, and characteristic “cherry-red spots.” Subtypes (II and III) of Gaucher Disease, which result from a
deficiency in glucocerebrosidase, can cause devastating and
rapid neurological deterioration. Neuroimaging is usually
normal in patients with Gaucher Disease, but EEG can show
several abnormalities including polyspikes with occipital
predominance sensitive to photostimulation, diffuse slowing
with high-voltage sharp waves during sleep, and multifocal
spike-and-wave paroxysms [100, 101].
3.2.3. Gangliosidosis and Tay-Sachs Disease. Tay-Sachs disease is an example of defects involving the degradation
of gangliosides, which are vital signaling, transport, and
regulatory proteins in the lysosomal membrane. Seizures
typically begin within the first year of life and worsen in
frequency and severity. They are difficult to control with
antiepileptics and can acutely and rapidly progress; in these
cases, EEG and clinical deterioration can follow until death
[102].
3.3. Peroxisomal Diseases. As a participant in cellular detoxification, lipid metabolism, as well as myelin, neuronal function, migration, and brain development [103], peroxisomes
are essential for neuronal health. Nearly all peroxisomal disorders (Table 12) are known to impair neurological function,
though peroxisomes are present in almost all eukaryotic cells,
and consequently its associated diseases will also manifest
in multiple organ systems. Seizures occur particularly in the
neonatal period and may be a result of cortical migration
defects. Symptomatic treatment using anticonvulsants is the
predominant therapy [104, 105].
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Mitochondria

HCO3 + NH4 + 2 ATP
CPSI

N-acetylglutamate

Cytoplasm

Carbamoyl
phosphate
OTC

Aspartate
Citrulline

Citrulline

Ornithine

NO
NOS

Ornithine

ASS
Argininosuccinate
ASL

Urea

ARG

Arginine
Fumarate

Figure 6: The urea cycle. The urea cycle is a pathway of cytosolic and mitochondrial proteins involved in the conversion of ammonia
(NH4 ) to urea for excretion via the kidneys. The enzymes in the pathway are as follows: carbamoylphosphate synthetase (CPS1), ornithine
transcarbamylase (OTC); argininosuccinic acid synthase (ASS); argininosuccinic acid lyase (ASL); arginase I (ARG); nitric oxide synthase
(NOS). Pearl [2].

3.3.1. Rhizomelic Chondrodysplasia Punctata. Rhizomelic
chondrodysplasia punctata is a peroxisomal biogenesis disorder characterized by white matter abnormalities including inflammatory demyelination and noninflammatory dysmyelination, as well as cerebellar degeneration and loss of
Purkinje cells, leading to profound intellectual deficiency.
Almost all patients develop seizures, with nonspecific EEG
findings. Neurological defects and degeneration are severe,
and most individuals do not survive the first two years of life
[106].
3.4. Leukodystrophies. Genetic leukoencephalopathies, or
inherited white matter disorders, are diseases that primarily
affect myelinated structures in the brain and peripheral
nervous system. The majority of leukodystrophies primarily
feature motor dysfunction rather than encephalopathy, particularly early on in the development of the disease. Epilepsy,
however, can be a prominent symptom in certain classic
leukodystrophies (Table 13) such as Alexander’s disease. This
is associated with defects in the GFAPgene encoding astrocyte intermediate filaments. Early onset forms of Alexander’s
disease (Type I) frequently feature seizures, particularly
associated with fever, that are difficult to control. The clinical
course of type I Alexander’s disease is normally progressive
neurodegeneration involving megalencephaly, psychomotor
retardation, and spastic paraplegia [107].

4. Conclusion
Epileptic encephalopathies represent a challenging area of
pediatric neurology and epilepsy and have a broad differential diagnosis [108]. There are protean inborn errors of

metabolism which may lead to epileptic encephalopathies.
They have various degrees of treatability at present, with some
requiring prompt diagnosis and intervention to avoid otherwise catastrophic outcomes. The epileptologist may view
these from the viewpoint of syndromic phenotypes. In general, early myoclonic encephalopathy and myoclonic seizures
represent a classic epilepsy syndrome and seizure type,
respectively, associated with inborn errors of metabolism. Yet,
the phenotypic spectrum of epilepsy caused by hereditary
metabolic disorders is wide and includes refractory neonatal
seizures, early infantile epileptic encephalopathy (syndrome
of Ohtahara), infantile spasms, and progressive myoclonic
epilepsies, as well as syndrome variations such as early
onset absence epilepsy in glucose transporter deficiency. A
careful approach to metabolic disorders is helpful to consider
the various diseases that may present and develop into an
epileptic encephalopathy.
The small molecule disorders include amino and organic
acidopathies such as maple syrup urine disease, homocysteinemia, multiple organic acid disorders, and cobalamin deficiencies. Dietary intervention is key in preventing
encephalopathy in maple syrup urine disease and glutaric
aciduria, and hydroxycobalamin has a therapeutic role starting in prenatal intervention in cobalamin C deficiency.
Neurotransmitter and fatty acid oxidation disorders may
result in epileptic encephalopathies, and mitochondrial disorders present with a range of epilepsy phenotypes, including
intractable epilepsy and epilepsia partialis continua in polymerase gamma mutations. Cerebral folate deficiency appears
to result from a variety of causes but primary deficiency,
associated with mutations of the folate receptor or blocking
antibodies, has a phenotype of intractable generalized tonicclonic seizures in infancy which may respond to folinic acid.
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Table 11: Lysosomal storage disorders.

Storage materials

Diseases

Primary defect

Lipids
Monosaccharides

Niemann Pick C
Free sialic acid storage disease
(i) infantile free sialic acid storage disease (ISSD)

Intracellular cholesterol transport
Lysosomal transport protein sialin

(ii) intermediate salla disease
(iii) mild form (salla disease)
Mucolipidoses

Mucolipidosese
(i) type II (I cell disease)
(ii) type III (pseudo Hurler polydystrophy)
(iii) type IV

Mucopolysaccharidoses (MPS)

MPS

Dermatan, heparan sulfate
Dermatan, heparan sulfate
Heparan sulfate

(i) type IH (Hurler)
(ii) type II (Hunter)
(i) type III A (Sanfilippo type A)
(ii) type III B (Sanfilippo type B)

Dermatan, heparan, chondroitin
sulphate
Multiple enzyme defects

L-iduronidase
Iduronate-sulfatase
Heparan-N-sulfatase
N-acetyl-𝛼-glucosaminidase

(iii) type III C (Sanfilippo type C)

𝛼-glucosaminide-acetyl-CoA transferase

(iv) type III D (Sanfilippo type D)

N-acetylglucosamine-6-sulfatase

(i) type VII (Sly)

𝛽-Glucuronidase

Multiple sulfatase deficiency

Sulfatase-modifying factor-1 (SUMF1)
𝛽-Galactosidase and neuraminidase
secondary to defect of protective protein,
cathepsin A

Galactosialidosis
Neuronal ceroid lipofuscinosis
(NCL)

N-acetylglucosamine-1phosphotransferase
N-acetylglucosamine-1phosphotransferase
Receptor-stimulated cat ion channel
(mucolipidin)

NCL
(i) congenital

Cathepsin D (CTSD)

(ii) infantile (INCL)

Palmitoyl-protein thioesterase-1 (PPT1)

(iii) late infantile (LNCL)

Tripeptidyl peptidase 1 (TPP1)

(iv) juvenile (JNCL)

A transmembrane protein
Ceroid lipofuscinosis neuronal protein 3
(CNT3)
Ceroid lipofuscinosis neuronal protein 8
(CLN8)

(v) adult (ANCL)
(vi) Northern epilepsy (NE)
Oligosaccharidoses (glycoproteinoses)
Alpha-mannosidosis

𝛼-Mannosidase

Beta-mannosidosis

𝛽-Mannosidase

Fucosidosis

𝛼-Fucosidase

Schindler disease

𝛼-N-acetylgalactosaminidase

Aspartylglucosaminuria (AGU)

Aspartylglucosaminidase

Sialidosis
(i) severe infantile

𝛼-Neuraminidase

(ii) mild infantile (mucolipidosis I)

𝛼-Neuraminidase

(iii) adult

𝛼-Neuraminidase

Sphingolipidoses
Ceramide
Galactocerebroside

Farber disease
Ceramidase
Globoid Cell Leukodystrophy (GLD or Krabbe disease) 𝛽-Galactocerebrosidase
(i) infantile
(ii) late infantile
(iii) adult
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Table 11: Continued.

Storage materials
Gangliosidoses

Diseases

Primary defect

(iv) Saposin A deficiency

Sphingolipid activator protein A (SAPA)

GM1 gangliosidoses
(i) infantile

𝛽-Galactosidase

(ii) late infantile
(iii) adult

Glucocerebroside

GM2 gangliosidoses

𝛽-Hexosaminidase

(i) Sandhoff disease

𝛽-Hexosaminidase A and B (𝛼-subunit)

(ii) Tay Sachs

𝛽-Hexosaminidase A (𝛽-subunit)

(iii) GM2 activator deficiency

𝛽-Hexosaminidase activator

Gaucher disease
(i) type II

𝛽-Glucocerebrosidase

(ii) type III
Sphingomyelin

(iii) Saposin C deficiency

Sphingolipid activator protein C

Niemann-Pick
(i) type A

Sphingomyelinase

(ii) type B
Sulfatide

Metachromatic leukodystrophy (MLD)
(i) late infantile

Arylsulfatase A

(ii) juvenile
(iii) adult
(iv) Saposin B deficiency
Multiple sphingolipids

Sphingolipid activator protein B
Precursor of Sphingolipid activator
protein

Prosaposin deficiency (pSap)

Adapted from Pearl [2].

Table 12: Peroxisomal disorders.
Biogenesis disorders

Zellweger spectrum disorders (ZSD)
(i) Zellweger syndrome (ZS)
(ii) Neonatal adrenoleukodystrophy (NALD)
(iii) Infantile refsum disease (IRD)
Rhizomelic chondrodysplasia punctata (RCDP)

Single enzyme disorders
X-linked adrenoleukodystrophy (X-ALD)
Acyl-coA oxidase deficiency
Bifunctional protein deficiency (D-BP)
Alkyl-DHAP synthase deficiency
DHAP-alkyl transferase deficiency
Adult Refsum disease (classic)
Glutaric aciduria type III
Acatalasemia
Hyperoxaluria type I

Contiguous gene syndrome

Contiguous ABCD1 DXS1357E deletion
syndrome (CADDS)

Adapted from Pearl [2].

Table 13: Leukodystrophies including epilepsy as a manifestation.
Disorder
Alexander’s disease
Globoid cell leukodystrophy (Krabbe disease)
X-linked adrenoleukodystrophy
Hereditary diffuse leukoencephalopathy with spheroids
Metachromatic leukodystrophy

Disorders of serine synthesis may respond to pre- and postnatal supplementation with serine and glycine. There are several

potassium channelopathies involving the pancreas and brain,
presenting either with neonatal diabetes or hypoglycemia,
specifically (developmental delay, epilepsy, and neonatal diabetes) DEND and (hyperinsulinism-hyperammonemia) HIHA with specific therapeutic implications. Glucose transporter deficiency appears to be the prototype of transport
defects causing epilepsy and having specific therapy, in this
case being the ketogenic diet to supply an alternative brain
fuel to glucose, and the disorders related to the pyridoxine
vitamers, specifically pyridoxine and pyridoxal-5-phosphate,
require prompt identification and therapy to avert a catastrophic outcome. Autosomal recessively inherited deficiency
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of MTHFR may be reversible with use of betaine, whereas
other small molecule defects causing epileptic encephalopathy, for example, glycine encephalopathy and sulfite oxidase
deficiency, have no specific therapy at this time.
Large molecule disorders involve a complex constellation
of disorders of glycosylation, lysosomal storage diseases,
and peroxisomal disorders. Those including severe epilepsy
include Walker-Warburg syndrome, Fukuyama congenital
muscular dystrophy, gangliosidoses such as Tay-Sachs and
Sandhoff diseases, and the neuronal ceroid lipofuscinoses.
While epilepsy represents significant gray matter involvement in neurological disease, seizures can be a prominent
aspect of leukodystrophies such as Alexander’s disease. The
epileptologist should consider these hereditary disorders in
the investigation of patients with epileptic encephalopathies,
leading to specific diagnostic steps and, in some cases,
potential therapeutic maneuvers to address the metabolic
defect.
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